Huge variations between countries in time for reimbursement decisions on new cancer drugsAccess20 October 2018
Delays in access to new cancer medicines and unjustifiable price rises for old ones disadvantage patients unnecessarilyAccess28 January 2017
EMA reconsiders and gives its positive opinion for the approval of ixazomibAccess, Myeloma17 September 2016
MPE encourages EMA to review its negative recommendation for ixazomibAccess, MPE, Myeloma16 August 2016
